Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D. Roué G, et al. Among authors: rosich l. Blood. 2011 Jan 27;117(4):1270-9. doi: 10.1182/blood-2010-04-278853. Epub 2010 Nov 24. Blood. 2011. PMID: 21106982 Free article.
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S, López-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roué G, Campo E, Colomer D. Xargay-Torrent S, et al. Among authors: rosich l. Clin Cancer Res. 2013 Feb 1;19(3):586-97. doi: 10.1158/1078-0432.CCR-12-1935. Epub 2012 Dec 11. Clin Cancer Res. 2013. PMID: 23231952
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A, Xargay-Torrent S, López-Guerra M, Rosich L, Pérez-Galán P, Salaverria I, Beà S, Kalko SG, de Frias M, Campàs C, Roué G, Colomer D. Montraveta A, et al. Among authors: rosich l. Oncotarget. 2014 Feb 15;5(3):726-39. doi: 10.18632/oncotarget.1455. Oncotarget. 2014. PMID: 24519895 Free PMC article.
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Montraveta A, Xargay-Torrent S, Rosich L, López-Guerra M, Roldán J, Rodríguez V, Lee-Vergés E, de Frías M, Campàs C, Campo E, Roué G, Colomer D. Montraveta A, et al. Among authors: rosich l. Oncotarget. 2015 Aug 28;6(25):21159-72. doi: 10.18632/oncotarget.4230. Oncotarget. 2015. PMID: 26110568 Free PMC article.
Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Matas-Céspedes A, Rodriguez V, Kalko SG, Vidal-Crespo A, Rosich L, Casserras T, Balsas P, Villamor N, Giné E, Campo E, Roué G, López-Guillermo A, Colomer D, Pérez-Galán P. Matas-Céspedes A, et al. Among authors: rosich l. Clin Cancer Res. 2014 Jul 1;20(13):3458-71. doi: 10.1158/1078-0432.CCR-14-0154. Epub 2014 May 5. Clin Cancer Res. 2014. PMID: 24799524
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S, López-Guerra M, Rosich L, Montraveta A, Roldán J, Rodríguez V, Villamor N, Aymerich M, Lagisetti C, Webb TR, López-Otín C, Campo E, Colomer D. Xargay-Torrent S, et al. Among authors: rosich l. Oncotarget. 2015 Sep 8;6(26):22734-49. doi: 10.18632/oncotarget.4212. Oncotarget. 2015. PMID: 26068951 Free PMC article.
22 results